ForeBatten2020

Available for Purchase

BUY TICKETS

Browse, Bid & Buy

VIEW ITEMS

Not Attending?

You can still participate in the auction!

Donate Now

Help our cause by contributing to our fundraising efforts.

No act of generosity is too small to make a difference.

$50

$100

$250

$500

$1,000

$2,500

Donor & Payment Information

Already have an account? Sign in

Email required

Select from the payment options below:

Terms and Conditions required

I have read and agree to the Terms and Conditions and Privacy Policy and give my consent to ForeBatten Foundation to process my personal data. I understand I can revoke this consent at any time.

Donor approves the payments of any charitable donations and/or purchases to ForeBatten Foundation in the amount set forth therein.

Subtotal:

Transaction Fees:

0.0

Total:

I will pay the fees

By paying the transaction fee, you ensure more money goes to your organization’s mission.

Your credit card statement will reflect charges from ‘ForeBatten Foundation’

Cancel

We welcome item donations!

Donate an Item Now

Take a Swing ForeBatten 3

March 2nd, 2020

Read out story on Golf.com

Silent auction bidding ends March 2nd at 8:30 pm MT (last raffle ticket will be sold at 7:30 pm MT)

Event Timeline (MST)

5:30 pm - Registration
5:30 pm - Golf & Open Bar
6:00 pm - Dinner Buffet
7:30 pm - A Message From Our Scientific Team
8:30 pm - Silent Auction Closes & Opportunity Drawing Winners Announced
9:00 pm - Event Concludes

What are we raising money fore?

Thanks to YOUR generosity, ForeBatten Foundation is actively sponsoring research aimed directly at CLN3-Batten disease.

ASOs

This study, with Dr. Michelle Hastings, supports the testing of an approach to correct CLN3 gene expression using a nucleic acid drug platform called antisense oligonucleotides (ASO). These molecules are designed to target CLN3 with the aim of inducing the production of functional proteins from the defective gene as a way to prevent neurodegeneration.

SMALL MOLECULES

We are also funding research in the Weimer lab, centered on identifying novel therapies for the treatment of CLN3-Batten disease including small molecules & ASO's. To better define whether selected drug targets are improving efficacy and rescuing CLN3 function, the team is using an approach called BioID, which relies of proximity-based labeling, to map the CLN3 protein interactome.

GENE THERAPY

ForeBatten is advocating for gene therapy research, focusing on pre-clinical studies of innovative AAV delivery methods to find the most effective and safe way to reach as many neuronal cells as possible. While our emphasis is CLN3-Batten Disease, this research will ultimately help many patients suffering from a wide range of neurodegenerative diseases.

To learn more about the Kahn Family and Batten disease, visit www.forebatten.org